The handle [http://hdl.handle.net/1887/29024](http://hdl.handle.net/1887/29024) holds various files of this Leiden University dissertation

**Author:** Fontein, Duveken Berthe Yvonne  
**Title:** Tailoring endocrine treatment for early breast cancer  
**Issue Date:** 2014-10-14
TAILORING ENDOCRINE TREATMENT FOR EARLY BREAST CANCER

Duveken B.Y. Fontein
TAILORING ENDOCRINE TREATMENT FOR EARLY BREAST CANCER

Duveken B.Y. Fontein
TAILORING ENDOCRINE TREATMENT FOR EARLY BREAST CANCER

PROEFSCHRIFT

ter verkrijging van de graad van Doctor aan de Universiteit Leiden,
op gezag van Rector Magnificus prof.mr.dr. C.J.J.M. Stolker,
volgens besluit van het College voor Promoties
te verdedigen op dinsdag 14 oktober 2014

clokke 15:00 uur

door
Duveken Berthe Yvonne Fontein
egeboren te Kogarah (Australië) in 1984
PROMOTIECOMMISSIE

PROMOTOORES
prof. dr. C.J.H. van de Velde
prof. dr. J.W.R. Nortier

CO-PROMOTOR
dr. C. Seynaeve Erasmus MC, Rotterdam

OVERIGE LEDEN
prof. dr. E. van der Wall Universitair Medisch Centrum Utrecht
prof. dr. ir. J.J.M. van der Hoeven
prof. dr. V.T.H.B.M. Smit
prof. dr. H. Putter
dr. E. Bastiaanet
CONTENTS

INTRODUCTION

Chapter 1. General introduction and outline of this thesis 7

PART I. PATIENT AND TUMOR CHARACTERISTICS

Chapter 2. Preferential endocrine therapy for postmenopausal early breast cancer patients: a Dutch and Belgian TEAM trial sub-study 19

Chapter 3. Influence of semi-quantitative estrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer 33

Chapter 4. Body-mass index as a prognostic indicator in breast cancer patients treated with adjuvant endocrine therapy: an international TEAM trial analysis 49

Chapter 5. Age and the effect of physical activity on breast cancer survival: a systematic review 65

Chapter 6. Age in relation to physical activity and survival in postmenopausal hormone receptor-positive breast cancer patients – results of the TEAM-lifestyle study 81

Chapter 7. Dynamic prediction in breast cancer – proving feasibility in clinical practice using the TEAM trial 97

PART II. QUALITY OF LIFE, TREATMENT COMPLIANCE AND SIDE EFFECTS

Chapter 8. Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients – a TEAM trial sub-study 117

Chapter 9. High non-compliance in patients treated with extended adjuvant letrozole. Results from the IDEAL randomized trial 131

Chapter 10. Relationship between specific adverse events and efficacy of exemestane therapy in early postmenopausal breast cancer patients 145
Chapter 11. Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors – an international TEAM trial analysis

Chapter 12. Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a sub-study of Dutch TEAM trial patients

PART III. PRE-OPERATIVE AND OPERATIVE TREATMENT POSSIBILITIES

Chapter 13. Neoadjuvant endocrine therapy in endocrine-sensitive breast cancer – a systematic review

Chapter 14. Efficacy of six months neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients – a phase II trial

Chapter 15. Timing of the sentinel lymph node biopsy in breast cancer patients receiving neoadjuvant therapy – recommendations for clinical guidance

DISCUSSION

Chapter 16. General discussion

APPENDICES

Summary in English and Dutch (Nederlandse samenvatting)
Acknowledgements (Dankwoord)
List of Publications
Curriculum Vitae